These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24021375)

  • 1. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
    Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
    Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib-induced neutrophilic panniculitis.
    Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
    Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
    West ES; Williams VL; Morelli JG
    Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panniculitis in patients treated with BRAF inhibitors: a case series.
    Choy B; Chou S; Anforth R; Fernández-Peñas P
    Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
    Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
    [No Abstract]   [Full Text] [Related]  

  • 12. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
    Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
    Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RASopathic alopecia: hair changes associated with vemurafenib therapy.
    Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
    J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
    [No Abstract]   [Full Text] [Related]  

  • 15. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
    Kim GH; Levy A; Compoginis G
    J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic epidermal necrolysis induced by vemurafenib.
    Lapresta A; Dotor A; González-Herrada C
    Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
    [No Abstract]   [Full Text] [Related]  

  • 20. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
    Grey A; Cooper A; McNeil C; O'Toole S; Thompson J; Grimison P
    Intern Med J; 2014 Jun; 44(6):597-600. PubMed ID: 24946815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.